Cancer Genetics Reports Q3 Financial Results
Cancer Genetics has reported its Q3 strategic, financial and operating results for the third quarter ended September 30, 2019.
Spring Bank Doses Patients in Phase 1 Clinical Trial of SB 11285
The company announced it has started dosing patients in its Phase 1 clinical trial of SB 11295 in patients with...
Fluidigm Announces Pricing of Private Offering
The company announced the pricing of US$50 million aggregate principal amount of 5.25 percent convertible senior notes due 2024.
Relevium Launches LeefyLyfe™ Organic Hemp Products in the US
Relevium Technologies Inc. (TSXV:RLV, OTCQB:RLLVF) is pleased to announce the launch of LeefyLyfeTM Organics.
Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx(TM) 100
Cardiol Therapeutics Inc. is pleased to announce the formation of the Clinical Steering Committee for a Phase 2 international trial.
Enlivex Therapeutics Finishes Recruitment for Phase 1b Trial
Enlivex Therapeutics' Phase 1b clinical trial is evaluating the company's Allocetra in patients with severe sepsis.
Ontario Pharmacists and Avricore Health Partner to Expand HealthTab™ in Community Pharmacies and Enhance Patient Care
Avricore Health Inc. and the Ontario Pharmacists Association are pleased to announce a Memorandum of Understanding.